- Home
- ANIX
as 02-21-2025 4:00pm EST
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 82.7M | IPO Year: | 1987 |
| Target Price: | $8.50 | AVG Volume (30 days): | 118.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.07 - $4.20 | Next Earning Date: | 03-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Anixa Biosciences Inc. (ANIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baskies Arnold M | ANIX | Director | Jan 28 '25 | Buy | $2.82 | 5,000 | $14,100.00 | 120,000 | |
| Titterton Lewis H jr | ANIX | Director | Jan 23 '25 | Buy | $2.96 | 3,000 | $8,820.00 | 932,334 | |
| Titterton Lewis H jr | ANIX | Director | Jan 22 '25 | Buy | $3.01 | 2,000 | $6,020.00 | 932,334 | |
| Titterton Lewis H jr | ANIX | Director | Jan 21 '25 | Buy | $2.59 | 6,000 | $15,540.00 | 932,334 | |
| Titterton Lewis H jr | ANIX | Director | Jan 17 '25 | Buy | $2.57 | 10,000 | $25,700.00 | 932,334 | |
| Catelani Michael | ANIX | President, COO, & CFO | Jan 15 '25 | Buy | $2.15 | 9,289 | $19,971.35 | 44,500 | |
| KUMAR AMIT | ANIX | Chief Executive Officer | Jan 15 '25 | Buy | $2.23 | 43,000 | $95,890.00 | 559,925 |
Latest Anixa Biosciences Inc. News
ANIX Breaking Stock News: Dive into ANIX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
PR Newswire
4 days ago
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
PR Newswire
8 days ago
Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview
PR Newswire
11 days ago
Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum
PR Newswire
18 days ago
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention
PR Newswire
a month ago
Anixa Biosciences CEO Provides Letter to Shareholders
Simply Wall St.
a month ago
Anixa Biosciences Leads 3 Promising Penny Stocks On US Exchanges
Simply Wall St.
a month ago
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Compare ANIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIX Anixa Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.